Recombinant Anti-VEGF Receptor 1 antibody [Y103] - Low endotoxin, Azide free (ab184784)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [Y103] to VEGF Receptor 1 - Low endotoxin, Azide free
- Suitable for: IP, WB, IHC-P
- Reacts with: Mouse, Rat, Human, Chinese hamster
Overview
-
Product name
Anti-VEGF Receptor 1 antibody [Y103] - Low endotoxin, Azide free
See all VEGF Receptor 1 primary antibodies -
Description
Rabbit monoclonal [Y103] to VEGF Receptor 1 - Low endotoxin, Azide free -
Host species
Rabbit -
Tested applications
Suitable for: IP, WB, IHC-Pmore details
Unsuitable for: Flow Cyt or ICC/IF -
Species reactivity
Reacts with: Mouse, Rat, Human, Chinese hamster -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
(Peptide available asab182457) -
Positive control
- Mouse brain tissue, A431 cells, skin cancer.
-
General notes
ab184784 is the carrier-free version of ab32152.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Our Low endotoxin, azide-free formats have low endotoxin level (≤ 1 EU/ml, determined by the LAL assay) and are free from azide, to achieve consistent experimental results in functional assays.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Storage buffer
pH: 7.20
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
Y103 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Anti-VEGF Receptor 1 antibody [Y103] - BSA and Azide free (ab210608)
- Alexa Fluor® 488 Anti-VEGF Receptor 1 antibody [Y103] (ab309078)
- Alexa Fluor® 555 Anti-VEGF Receptor 1 antibody [Y103] (ab309079)
- Alexa Fluor® 647 Anti-VEGF Receptor 1 antibody [Y103] (ab309080)
- Anti-VEGF Receptor 1 antibody [Y103] (ab32152)
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab184784 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
Use at an assay dependent concentration.
|
|
WB |
Use at an assay dependent concentration. Detects a band of approximately 180 kDa (predicted molecular weight: 151 kDa).
Please check the parent abID, ab32152, for more information on dilutions. |
|
IHC-P |
Use at an assay dependent concentration.
|
Notes |
---|
IP
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. Detects a band of approximately 180 kDa (predicted molecular weight: 151 kDa). Please check the parent abID, ab32152, for more information on dilutions. |
IHC-P
Use at an assay dependent concentration. |
Target
-
Function
Receptor for VEGF, VEGFB and PGF. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. Isoform SFlt1 may have an inhibitory role in angiogenesis. -
Tissue specificity
Mostly in normal lung, but also in placenta, liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform sFlt1 is strongly expressed in placenta. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Cellular localization
Secreted and Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 2321 Human
- Entrez Gene: 14254 Mouse
- Entrez Gene: 54251 Rat
- Omim: 165070 Human
- SwissProt: P17948 Human
- SwissProt: P35969 Mouse
- SwissProt: P53767 Rat
- Unigene: 594454 Human
see all -
Alternative names
- EC 2.7.10.1 antibody
- FLT 1 antibody
- FLT antibody
see all
Images
-
Anti-VEGF Receptor 1 antibody [Y103] - Low endotoxin, Azide free (ab184784) + Mouse brain lysate at 15 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) (ab97051)
Predicted band size: 151 kDa
Exposure time: 8 secondsBlocking buffer and concentration: 5% NFDM/TBST
Diluting buffer and concentration: 5% NFDM/TBST
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 1 antibody [Y103] - Low endotoxin, Azide free (ab184784)
Immunohistochemical analysis of paraffin-embedded Human gastric carcinoma tissue labeling VEGF with ab32152, followed by a ready to use Goat Anti-Rabbit IgG H&L (HRP). Cytoplasmic staining on human gastric carcinoma. Counterstained with Hematoxylin. Heat mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0).
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is a ready to use Goat Anti-Rabbit IgG H&L (HRP).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32152).
-
VEGF Receptor 1 was immunoprecipitated from 0.35 mg mouse brain lysate 10μg with ab32152 at 1:30 dilution (2μg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab32152 1:1000 dilution (2 μg/ml). VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1:1000 dilution.
Lane 1: Mouse brain lysate 10μg.
Lane 2: ab32152 IP in mouse brain lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab32152 in mouse brain lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 1 second.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32152).
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 1 antibody [Y103] - Low endotoxin, Azide free (ab184784)Image from Sano M et al. PLoS ONE. 2014 Mar 20; 9(3). Fig 2E. DOI 10.1371/journal.pone.0089830. Lymphangiogenesis and Angiogenesis in Abdominal Aortic Aneurysm. e89830.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human abdominal aortic aneurysm (AAA) wall tissue sections labeling VEGF Receptor 1 with ab32152 at 1/100 dilution.
Resected aortic tissues were immersed in 10% neutral buffered formalin for at least 24 h for immunohistochemical staining. Tissue sample was embedded in paraffin; 4 µm sections were cut and mounted onto MAS-coated slides. The sections were deparaffinized, dehydrated, and boiled in a pressure cooker in 0.01 M citric acid buffer (pH 6.0) for 20 min. The sections were washed with phosphate-buffered saline and incubated with 3% H2O2 in absolute methanol for 5 min to inhibit any endogenous peroxidase activity. Sections were preincubated with 3% normal goat serum for 20 min to minimize nonspecific binding to VEGF Receptor 1, and incubated with ab32152 at 4°C overnight in a moist chamber. The section was washed with phosphate-buffered saline and then incubated with the appropriate secondary antibody for 30 min at room temperature. Staining was visualized with Vector DAB, and tissue section was then counterstained with hematoxylin.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32152).
Protocols
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (24)
ab184784 has been referenced in 24 publications.
- Li L et al. Effect of Azelaic Acid on Psoriasis Progression Investigated Based on Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (AKT) Signaling Pathway. Clin Cosmet Investig Dermatol 15:2523-2534 (2022). PubMed: 36447569
- Zhang Q et al. miR-194-5p protects against myocardial ischemia/reperfusion injury via MAPK1/PTEN/AKT pathway. Ann Transl Med 9:654 (2021). PubMed: 33987352
- Yin J et al. Chronic atrophic gastritis and intestinal metaplasia induced by high-salt and N-methyl-N'-nitro-N-nitrosoguanidine intake in rats. Exp Ther Med 21:315 (2021). PubMed: 33717258
- Chen H et al. Fangchinoline attenuates cardiac dysfunction in rats with endotoxemia via the inhibition of ERK1/2 and NF-?B p65 phosphorylation. Ann Transl Med 8:1167 (2020). PubMed: 33241016
- Zhang X et al. Downregulation of MST4 Underlies a Novel Inhibitory Role of MicroRNA Let-7a in the Progression of Retinoblastoma. Invest Ophthalmol Vis Sci 61:28 (2020). PubMed: 32539131